NCT07215975

A Real-World Study to Evaluate Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle East

REal-World Application of Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle East (RELATE): A Non-interventional Retrospective and Prospective Observational Study

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 200 (estimated)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate luspatercept treatment in adults with transfusion-dependent beta-Thalassemia in the Middle East

Conditions

• β-thalassemia

Interventions

Type	Name	Description
DRUG	Luspatercept	According to the product label

Timeline

• Start date: 2026-02-26
• Primary completion: 2030-02-28
• Completion: 2031-04-17
• First posted: 2025-10-14
• Last updated: 2026-02-23

Locations

2 sites across 2 countries: Oman, Saudi Arabia

Regulatory

• FDA-regulated drug study